Drug intelligence / Profile preview

V-Omin

Development stage: Unknown
Lead developer: AJU Pharm

Overview

**V-Omin** is an AJU Pharm product/intervention associated with a completed Phase 4 study in non-proliferative diabetic retinopathy that evaluated combination treatment with B55R1 and B55R2 against B55R1 monotherapy over 24 weeks, with changes in retinal hard exudates as a key efficacy focus. Publicly available trial materials do not disclose V-Omin's active-ingredient composition, molecular target, pharmacologic mechanism, dosage form, or route of administration; therefore, no target-level mechanism can be assigned reliably. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230184))

Brand names: V-Omin

Beyond the preview

Go deeper on V-Omin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-Omin.

Explore the full profile